|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for IGFBP3(NM_000598.4) Search again
Product ID:
HQP009544
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
BP-53, IBP3
Gene Description:
insulin like growth factor binding protein 3
Target Gene Accession:
NM_000598.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
Gene References into function
- p53 induces the growth inhibitor IGF-binding protein 3 in apoptosis.
- This study defines a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity, requiring TGF-betaRII but not dependent on the nuclear translocation of IGFBP-3
- Hypothyroidism is associated with significant reductions of IGFBP-3
- Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells
- The upstream AP2-binding site of IGFBP3's promoter is specifically hypermethylated in hepatomas.
- interaction with STAT-1 during chondrogenesis
- Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.
- Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly.
- Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase
- induces early apoptosis and has potential tumor suppressive effects in prostate cancer
- study the changes of plasma insulin-like growth factor -1 (IGF-1) and IGF binding protein 3 (IGFBP3) in patients with acute cerebral infarct (ACI) and acute cerebral hemorrhage (ACH)
- A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation
- IGFBP-3 is essential for TNF-alpha-induced apoptosis in PC-3 cells
- identification of the proteolytic cleavage sites in circulating IGFBP-3
- determination of blood levels in adult patients with severe liver disease before and after orthotopic liver transplantation
- Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China.
- Enhanced expression in gastric cancer cells increases paclitaxel and etoposide-induced growth inhibition
- The amino-terminal region induces apoptosis of MCF-7 breast carcinoma cells.
- Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
- is inversely associated with benign prostatic hyperplasia risk
- Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
- circulating level of IGFBP3 is related to the extent of myocardial injury in patients with hypertrophic cardiomyopathy.
- high levels of IGFBP-3 predicted distant recurrence but not death in postmenopausal breast cancer patients and those with estrogen receptor-positive tumors
- expression increases during immortalization of cervical keratinocytes
- IGFBP-3 promoter is activated by Trichostatin A-upregulated Sp1
- Variable mid-region is responsible for the specific pro-apoptotic functions of IGFBP-3; phosphorylation may provide a mechanism for regulation of this action
- improves insulin resistance by GH-dependent and independent mechanisms
- HT29 tumor cell proliferation in vitro was due, at least in part, to surgery-related depletion of insulin-like growth factor binding protein 3 in peripheral blood.
- These results provide evidence that a specific intracellular signal is triggered by IGFBP-3 binding to a cell surface receptor.
- role in breast cancer cell growth - review
- Hypermethylation of IGFBP-3 promoter is associated with non-small cell lung cancer
- IGFBP-3 concentration significantly lower in acute ischemic stroke than in controls.
- data demonstrate for the first time that serum levels of IGFs (including free fractions) and IGFBPs are not increased in euthyroid Graves' patients with active thyroid eye disease
- Follicular fluid IGF-1 and IGFBP-3 levels were not significantly different among the groups; however, follicular fluid IGFBP-1 levels were lower in those patients with moderate/severe endometriosis
- quantities of IGFBP-3 produced in culture by human cartilage are small compared with the amount supplied in the form of "small complexes" from the circulation
- Augmented serum levels of the IGF-I/IGF-binding protein-3 ratio in pre-menopausal patients with type I breast cysts.
- IGFBP-3 supports myoblast differentiation
- IGFBP-3 mRNA and protein are differentially expressed in distinct human brain microvascular endothelial cells populations.
- isolated amino-terminal and carboxyl-terminal domains of IGFBP-3 cooperate in the presence of IGFs to form high-affinity complexes that retain the ability to block IGF activity.
- Divergent influences of sex steroids, IGF-1, and IGFBP3 on age-related changes in lean body mass in healthy elderly men and women.
- endurance training improves glucose disposal and increases insulin-like growth binding protein-1 and -3 in men
- The IGFBP-3 -202 A/C polymorphism was not associated with susceptibility to prostate cancer.
- Polymorphic variation in IGFBP3 is associated with breast cancer risk.
- During Tamoxifen treatment, IGFBP-3 proteolysis was increased in breast cancer.
- IGFBP-3 degrading by MMP might have widespread consequences for the behavior of epidermal keratinocytes.
- IGFBP-3 can bind to LTBP-1 and provide a potential mechanism whereby IGFBP-3 can interact with the TGF-beta system
- functional effects of Humanin-IGFBP-3 interaction on cell survival and apoptosis
- The metal-binding domain of IGFBP3 mediate cellular uptake and modulates apoptosis.
- Actions of IGFBP-3 are mediated by internalization via distinct endocytic pathways.
- LRP1 is the type V TGF-beta receptor and mediates growth inhibition by IGFBP-3
- Upregulated with exposure to bone microenvironment and linked to TGF-beta mediated cell proliferaton
- IGFBP-3 mRna expression is increased in endometriosis, compared to normal endomatrium.
- breast malignant explants showed the progesterone induced IGFBP-3/IGF-I index decrease; the decrease was most evident in malignant explants expressing progesterone receptor
- an apparent altered regulation of local IGFBP-3 production during malignancy
- IGFBP-3 plays a crucial role in regulating IGF-I bioavailability, promoting cell survival.
- IGFBP-3 directly triggers a specific intracellular signal in MCF-7 cells
- an important additional prognostic marker in serum in ovarian cancer
- Following severe burn, a shift occurs toward a predominant Th2 phenotype. Exogenous IGF-I/IGFBP-3 treatment partially reverses this response.
- Down-regulation of IGFBP-3 gene expression is associated with Prostatic Neoplasms
- IGFBP-3 is phosphorylated by tissue transglutaminase 2
- Interaction between IGFBP-3 and EGF receptor system is central to whether IGFBP-3 acts as growth stimulator or inhibitor in breast cancer cells. Therapies targeting EGFR may have increased efficacy in breast tumors expressing high levels of IGFBP-3.
- Renal cell carcinoma (RCC) expresses IGF-I and IGFBP-3 and is responsive to exogenous IGF-I stimulation. In metastatic RCC, autocrine IGF-I and IGFBP-3 stimulated and inhibited growth. IGF-I and IGFBP-3 possible treatment in advanced RCC.
- Pregnancy-proteolyzed IGFBP-3, despite forming normal ternary complexes, is less effective than intact IGFBP-3 in retarding IGF egress from the circulation.
- Reduced expression of IGFBP-3 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma may provide a partial explanation for the aggressive behavior and poor prognosis of these tumors in this genodermatosis.
- endogenous IGFBP-3 directly inhibits proliferation of human intestinal smooth muscle cells by activation of TGF-betaRI and Smad2, an effect that is independent of its effect on IGF-I-stimulated growth.
- Patients with typical Sotos syndrome show low plasma IGF-II, IGFBP-3, IGFBP-4, and increased proteolysis of IGFBP-3 in serum.
- Association between high IGF-I and IGFBP-3 levels and increased risk of breast cancer in premenopausal women.
- the IGFBP3 variants was not associated independently with colon cancer, but there was an association when examined with IRS1. The risk increased 70%.
- interference with Sp-1 transactivation by MeCP2 may contribute to the transcriptional defect of IGFBP-3 expression in NSCLC cells with methylated promoter
- These findings identify the repression of insulin-like growth factor binding protein 3 gene by EWS/FLI-1 as a key event in the development of Ewing's sarcoma.
- IGFBP3 polymorphism maybe associated with the level of blood IGFBP3 protein and an increase risk of breast cancer.
- Long-term use of both conjugated equine etrogens and raloxifene decreases serum IGF-I and the IGF-I/IGFBP-3 ratio, but raloxifene increases ISGFBP-3.
- Mutation analysis in patients with undescended testis revealed functionally deleterious mutations, which may be responsible for the abnormal phenotype in some of the patients. (review)
- Met proto-oncogene and insulin-like growth factor binding protein 3 have roles in metastasis of well-differentiated pancreatic endocrine neoplasms
- N- and C-terminal residues of IGFBP-3 have roles in regulating IGF complex formation and receptor activation
- The serum IGF-1 and IGFBP-3 levels were significantly elevated in esophageal cancer patients and there was a positive correlation between IGF-1 and IGFBP-3.
- Increased circulating IGF-1 and IGFBP-3 may be stimulators of atherosclerosis.
- IGFBP-3 levels decreased significantly six months after the iodine supplementation.
- Serum IGFBP-3 levels differed significantly between pubertal developmental stages.
- Increased breast epithelial IGFBP-3 expression is a feature of tumorigenesis with cytoplasmic immunoreactivity in the absence of significant nuclear localisation in IDCs and DCIS; IGFBP-3 suggested to be a potential mitogen
- plasminogen binds with high affinity to IGF-II and IGF-binding protein-3
- 1,25-dihydroxyvitamin D3-induced up-regulation of IGFBP-3 is not required for the growth inhibitory effects of 1,25D in prostate cancer cells grown in serum-containing media.
- The expression of certain IGFBP is significantly altered in renal cell carcinoma
- Insulin-like growth factor binding proteins 3 and 5 are xpressed in idiopathic pulmonary fibrosis and have a role in extracellular matrix deposition
- dysregulation of IGFBP-3 in patients with myelodysplastic syndromes
- DNA damage and hypoxia are two important physiologic activators of p53.
- IGFBP-3 is a target of transcriptional repression by DeltaNp63alpha and that this repression represents a mechanism by which tumors that overexpress p63 may be protected from apoptosis.
- Although IGFBP-3 and IGFBP-5 share much structural and functional homology, they can modulate distinct apoptotic pathways in human breast cancer cells.
- PTEN may inhibit antiapoptotic IGF actions not only by blocking the IGF-IGFR-induced Akt activity, but also by regulating expression of components of the IGF system, in particular, upregulation of IGFBP-3
- IEE (IGFBP-3 enhancer element) is a positive transcription regulatory element that contributes to the up-regulation of IGFBP-3 during cellular senescence
- The level of intact IGFBP-3 is decreased in inflammatory bowel disease with moderate to severe disease activity. This decrease may be linked to altered IGFBP-3 production or to increased cleavage by proteases other than MMP-9.
- Finds IGFBP3 2133C variant allele associated with lower circulating IGFBP-3 hormone levels and an increased risk of colorectal cancer.
- Preincubation of erythroid cells with thrombospondin 1 eliminated the inhibitory activity of IGFBP-3
- Maternal diabetes is not associated with suppressed levels of IGFBP-1 in cord serum.
- Increased breast cancer risk in women with promoter polymorphisms in IGF1 and IGFBP3 genes, with increased risk for individuals homozygous for both polymorphisms.
- IGF BP3 was associated with birth weight as measured in seconsd semestser amniotic fluid.
- Imbalance of IGF-1 and IGFBP-3 may play a role in hepatocarcinogenesis and tumor development of liver cirrhosis patients
- Loss of insulin-like growth factor-binding protein-3 expression is associated with head and neck carcinogenesis.
- In diabetics, nonglycosylated IGFBP-3 is degraded more rapidly than glycosylated IGFBP-3. By acting as substrate for IGFBP-3 protease, nonglycosylated IGFBP-3 protects endogenous, glycosylated IGFBP-3 from degradation, allowing total IGFBP-3 to increase.
- Impacts on insulin signaling pathway to Inhibited insulin-stimulated glucose uptake independent of IGFs and through nonnuclear mechanisms. inhibited insulin-stimulated glucose uptake in omental but not s.c. adipose tissue explants.
- insulin-like growth factor signaling is subject to negative regulation through IGF binding protein-3 and positive regulation by EGF
- IGFBP-3 mediates growth suppression signals via the TGF-beta and/or retinoblastoma protein pathways in hepatocellular carcinoma
- Using the rat insulinoma RINm5F cell line, we report the first studies in insulin-secreting cells that IGFBP-3 selectively suppresses multiple, key intracellular phosphorelays.
- IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer.
- IGFBP-3 is differentially expressed between stromal and epithelial components of normal and malignant colon, which may reflect its pro-apoptotic, IGF-I-independent effect on colonic epithelial cells.
- IGF-I and IGFBP-3 levels were positively associated with weight gain and height gain from birth to 3 months in small for gestational weight versus appropriate weight children.
- Rpb3 is a potential nuclear target of insulin-like growth factor binding protein-3
- IGFBP-3 expression was higher in less aggressive tumors, but was not associated with disease progression.
- an IGFBP-3 mutant with deleted leader sequence localizes within the nucleus, its abundance is regulated by the ubiquitin/proteasome pathway, nuclear IGFBP-3 can induce apoptosis
- C4-2 cell survival in an androgen-depleted environment may be facilitated through differential resistance to the apoptotic effects elicited by IGFBP-3
- there are several conserved residues in the IGFBP-5 N-terminal region that are critical for transactivation and IGFBP-2 and -3 also have strong transactivation activity in their N-domains
- The IGFBP3, hRas, JunB, Egr-1, Id1 and MIDA1 genes were up-regulated in psoriatic involved skin compared with uninvolved skin.
- IGFBP-3 has positive or negative effects on growth and survival dependent upon the status of cholesterol-stabilized integrin receptor complexes
- IGFBP-3 is a growth inhibitor molecule (news)
- Both addition of IGFBP-3 protein to cell cultures or enforced expression of IGFBP-3 in the HT29 colon carcinoma cell line inhibited nuclear factor kappa B (NF-kappaB) activation in response to the induction of apoptosis by TRAIL.
- By Northern blot, we confirm hypoxia-induced expression of insulin-like growth factor binding protein 3 (igfbp3), thioredoxin-interacting protein (txnip), neuritin (nrn1).
- results indicate a previously unrecognized and potentially important role for insulin-like growth factor binding protein 3(IGFBP-3) in the extracellular matrix
- High levels of IGFBP-3 is associated with an increased risk of prostate cancer
- IGFBP-1, IGFBP-3 and IGF-I show acute changes following a glucose load and there are marked gender differences in these responses.
- IGFBP-3 can induce apoptosis in an IGF-independent manner without being secreted or concentrated in the nucleus
- a novel functional androgen response element is present in the IGFBP-3 promoter that directly mediates androgen induction of IGFBP-3 expression
- A decrease in free insulin-like growth factor 1 and IGFBP-3 levels, along with increases in blood pressure, significantly influenced the presence of diabetic complications
- Blood level is not a marker for metabolic syndrome x.
- High plasma levels of IGF-1, IGF-2, and IGFBP-3 were associated with good prognosis in patients with advanced NSCLC.
- Low expression of IGFBP-3 is associated with hepatocellular carcinoma
- This study demonstrates a direct interaction of the IGF and TGF-beta systems in human renal carcinoma cells. The observations that IGF-I enhances the TGF-beta signaling and that TGF-beta promotes IGFBP-3 production
- Common genetic variation in the IGFBP3 gene does not substantially influence prostate and breast cancer susceptibility.
- Cleavage of IGFBP-3 in breast carcinoma tissues was correlated with ADAM28 expression levels and inhibited by treatment with ADAM inhibitor or anti-ADAM28 antibody.
- Genetic variation in IGFBP3 is associated with breast cancer risk
- IGFBP-3, IGFBP-4, and IGFBP-10/CYR61 mRNA levels were up-regulated in Barrett's and tumour tissue of oesophageal adenocarcinoma patients
- polymorphisms in the IGF-1R and IGFBP3 genes, but not IGF-1 or IGFALS, may be associated with altered survival among subgroups of breast cancer patients defined by menopausal status
- High IGF-II, IGFBP-3, IGFBP-4, and low PAPP-A levels in FF at the time of oocyte retrieval suggest better oocyte maturation and early embryo development.
- These results suggest that caspase-10, DR-3 and IGFBP-3 are involved in apoptosis in the preeclamptic placenta.
- Results showed that IGFBP-3 methylation played an important role in the silencing of its expression, suggesting that IGFBP-3 may act as a tumor suppressor gene in several human cancers examined.
- circulating levels may be lowered in patients with head and neck cancer
- plasma levels of IGF1 and IGFBP-3 vary by ethnic group and have roles in development of obesity
- results strongly suggest that IGFBP-3 expression may be a vital cell motility, migration, and proliferation factor necessary for melanoma metastasis and is an important biomarker in human melanoma
- exposure to hypoxia and acidosis at birth strongly correlated with a fall in IGF-1 and IGFBP-3 levels in cord blood
- the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis
- IGFBP-3 has potent insulin-antagonizing capability and suggest a role for IGFBP-3 in cytokine-induced insulin resistance and other mechanisms involved in the development of type-2 diabetes.
- Circulating low levels of total IGFBP-3 was associated with increased risk of incident coronary events in older adults.
- protective role of IGFBP-3 in risk of breast cancer
- CDX2 can function as a transcriptional repressor, and one mechanism by which CDX2 promotes anchorage-independent growth is by transcriptional repression of IGFBP-3.
- IGFBP-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms
- children with sickle cell anemia with poor growth had significantly more proteolyzed IGFBP-3 in serum compared to children with normal growth
- The role of GalNAc-T14 as an intracellular mediator of the effects of IGFBP-3 need to be verified in future studies.
- IGFBP-3 and Nur77 associate in the cytoplasmic compartment in 22RV1 human prostate cancer cells.
- normal breast epithelial cells can induce apoptosis of breast cancer cells through IGFBP-3 and maspin.
- Serum testosterone concentration and serum IGF-1/IGFBP-3 molar ratio are the major determinants of bone mineral density in boys at different pubertal stages.
- Methylation of IGFBP3 may be involved in the early stages of prostate cancer development.
- IGFBP-3 contributes to esophageal tumor development and progression through IGF-dependent and independent mechanisms.
- Severely deficient in a case of insulin-resistance syndrome (Rabson-Mendenhall type).
- Common genetic variation in IGFBP3 influences circulating levels of IGFBP-3 among African-Americans, Native Hawaiians, Japanese-Americans, Latinos, and whites.
- IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth.
- A 30-kDa proteolytic IGFBP-3 fragment was isolated from third trimester pregnancy human serum and identified by amino acid sequence analysis and mass spectrometry to correspond to residues 1-212 of the parent protein.
- large prospective study showed no overall association between the insulin-like growth factor axis and prostate cancer risk, however, IGF-1:IGFBP-3 molar ratio was related to risk for aggressive prostate cancer in obese men
- Insulin-like growth factor binding protein (IGFBP)-3 mRNA is more abundantly expressed in hypoxia-related inflammatory angiogenesis and recent in vivo data suggest that IGFBP-3 has direct, IGF-independent inhibitory effects on angiogenesis.
- These results suggest that IGFBP3 might play an important role in the cellular senescence of human umbilical vein endothelial cells as well as in vivo aging.
- [(125)I]-labeled IGFBP-2 and -3, but not IGFBP-1, were proteolyzed by Ca(2+)-activated m-calpain in vitro.
- Men who carry the IGFBP3 C allele were found to have a higher risk of developing prostate cancer compared to controls, and the association was grade specific in both ethnic groups
- No significant differences in levels in fibromyalgia patients.
- IGFBP-3 sensitizes prostate cancer cells to interferon-gamma (IFN-gamma)-induced apoptosis and inhibition of cell proliferation
- Serum levvels amd a single nucleotide polymorphism are indiative of prostate carcinogenesis.
- Perturbations in the IGF/IGFBP-3 axis may be potential additional targets for pharmacological manipulation in coronary heart disease.
- study reports a methylation-dependent upstream stimulatory factor (USF) binding site influencing the basal and insulin-stimulated transcriptional activity of the IGFBP3 promoter
- E7-mediated destruction of nuclear IGFBP-3 correlates with the inhibition of IGFBP-3-induced apoptotic cell death.
- In a group of older US men, a strong inverse association between IGFBP-3 and lower urinary tract symptoms was observed.
- Osteopenia is common in children with cerebral palsy and may be associated with lower IGF-1 and IGFBP-3 levels
- IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian endometrioid carcinoma.
- Serum IGFBP-3 was not altered in neonates with intrauterine growth retardation.
- The N-terminal IGF-binding protein-3 fragment induces apoptosis in human prostate cancer cells in an IGF-independent manner
- This study supports the role of IGFBP-1, -3 and -7 as potential tumour suppressor genes in human breast cancer.
- study established age- and sex-specific reference ranges for serum IGF-1 and IGFBP-3 levels
- no major role of the assessed genetic variation within the IGF1 and the IGFBP3 genes in CRC risk.
- microsatellite instability in CPG-island-metahylator-high colorectal cancers, & this relationship is limited to p53-negative tumors.
- in PC-3 cells, RXR-alpha is not required for the nuclear translocation of IGFBP-3 and that IGFBP-3 can induce apoptosis in human prostate cancer cells without binding RXR-alpha.
- The role of IGFBP-3 on senescence depends on the genetic background of the donor, and additional factors might be important to maintain the senescent phenotype.
- These findings suggest that serum levels of IGFBP-3 (and possibly IGF-I) are associated with the rate of HIV disease progression in women.
- A concurrence of elevated GH levels and decreased IGF-I, IGFBP-3, and total ghrelin levels during the early burn injury period.
- Higher early levels of the human milk IGF system might contribute to maturation of the infant gut.
- functional variants of insulin-like growth factor-binding protein-3 might be important markers for gastric cancer susceptibility
- IGFBP-3 regulates the appearance of several biomarkers of senescence after repeated exposures of WI-38 fibroblasts to tert-butylhydroperoxide and ethanol.
- data suggest that low concentrations of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) could be a reliable marker to differentiate benign from malignant ovarian tumors
- Levels of circulating insulin growth factor I (IGF-I) and insulin-like growth factor-binding protein 3 and breast cancer risk were investigated.
- IGFBP-3 promoter polymorphisms of -1590 C>A and -202 A>C might be a genetic risk factor for lung cancer
- The stroma--particularly reactivated stroma--is the main source of IGFBP-3 in the prostate, suggesting that this peptide acts as a mediator of stromal-epithelial interactions
- associations of some breast cancer risk factors with intact levels of IGFBP-3 are different from those with total (intact and fragmented) IGFBP-3 levels
- Low expression of IGFBP-3 mRNA in normal colonic mucosa predicts increased risk of adenomas
- This study suggests that there is an interaction between leptin, IGF-1, IGFBP-3 and insulin resistance in patients with chronic kidney disease.
- the association between common genetic variation in the IGFBP3 genes in relation to circulating IGFBP3 levels and breast cancer risk
- A new approach for designing protein delivery systems using IGFBP-3/5 derived peptides based on the molecular mechanisms of IGF-independent activities of IGFBPs.
- None of the components in the IGF-1 pathway including IGFBP3, PI3k, and PTEN influence the relation between IRS-1 genotype and prostate cancer risk. Ther is no association between carriage of the variant IRS-1 gene and prostate cancer risk.
- A high IGFI:IGFBP3 ratio was associated with increased benign prostate hyperplasia risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms.
- results did not support a relationship between GH T1663A and IGFBP3-202A/C with ischemic stroke in Chinese
- IGFBP-3(insulin-like growth factor binding protein 3)levels were significantly elevated in patients with Systemic Scleroderma compared with systemic lupus erythematosus or controls.
- insulin-like growth factor binding protein 3 has a role in progression of oral squamous cell carcinoma